Core Points - The company announced the implementation results of its share repurchase plan, which was initially proposed on September 24, 2024, and approved by the board and shareholders [1][2] - The total amount expected for the repurchase is between RMB 300 million and RMB 500 million, with a maximum repurchase price of RMB 12 per share [2][3] - The actual number of shares repurchased is 48,547,100, accounting for 1.70% of the total share capital, with a total expenditure of RMB 492.017 million [2][3] Repurchase Plan Details - The repurchase plan was approved during board meetings on September 23, 2024, and October 11, 2024, and the report was disclosed on October 12, 2024 [1] - The repurchase period is from November 11, 2024, to October 10, 2025 [1] - The repurchase price was adjusted to a maximum of RMB 11.824 per share after the 2024 semi-annual dividend distribution and further adjusted to RMB 11.398 per share after the 2024 annual dividend distribution [2] Implementation Status - The first repurchase occurred on October 23, 2024, and the plan was completed by September 2, 2025 [2][3] - The highest repurchase price was RMB 10.97 per share, and the lowest was RMB 9.10 per share, with an average price of RMB 10.13 per share [2] Impact of the Repurchase - The repurchase will not have a significant impact on the company's operations, finances, or future development, nor will it affect the company's listing status or control [3] Share Cancellation Arrangement - The company has completed the necessary procedures for notifying creditors regarding the cancellation of repurchased shares [4] - The total share capital will decrease from 2,852,788,750 shares to 2,804,241,650 shares after the cancellation of the repurchased shares [4] Shareholder Changes - Following the cancellation, the controlling shareholder Meng Qingshan and his concerted actors will see a change in their shareholding proportions [4] - Meng Qingshan's shareholding will increase from 29.94% to 30.46% after the cancellation [4]

格隆汇9月3日丨梅花生物(600873.SH)公布，截至2025年9月2日收盘，公司本次股份回购计划实施完 毕。公司已实际回购公司股份4854.71万股，占公司总股本（公司股本总数为2,852,788,750股）的 1.70%，回购最高价格为10.97元/股、最低价格为9.10元/股，回购均价10.13元/股，使用资金总额为 49,201.70万元（不含交易费用）。 ...

证券代码：600873 证券简称：梅花生物 公告编号：2025-054 梅花生物科技集团股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/9/24，由公司董事长王爱军提议 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2024 10 | 10 | 月 | 11 | 日~2025 | 年 | 10 | 日 | | 预计回购金额 | 30,000万元~50,000万元 | | | | | | | | | 回购价格上限 | 12元/股 | | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 实际回购股数 | 4,854.71万股 | | | | | | | | | 实际回购股 ...

Group 1 - The company, Meihua Biological (600873.SH), has completed its share repurchase plan as of September 2, 2025 [1] - A total of 48.5471 million shares were repurchased, accounting for 1.70% of the company's total share capital [1] - The highest repurchase price was 10.97 yuan per share, while the lowest was 9.10 yuan per share, with an average repurchase price of 10.13 yuan per share [1] - The total amount of funds used for the repurchase was 492 million yuan, excluding transaction fees [1]

智通财经APP讯，梅花生物(600873.SH)发布公告，截至2025年9月2日收盘，公司本次股份回购计划实 施完毕。公司已实际回购公司股份4854.71万股，占公司总股本的1.70%，回购最高价格为10.97元/股、 最低价格为9.10元/股，回购均价10.13元/股，使用资金总额为4.92亿元(不含交易费用)。 ...

梅花生物公告，公司于2024年10月11日至2025年10月10日期间实施股份回购计划。预计回购金额在3亿 元至5亿元之间，回购价格上限为12元/股。实际回购股数为4854.71万股，占总股本的1.70%，实际回购 金额为4.92亿元，价格区间为9.1元/股至10.97元/股。回购股份全部用于注销，减少注册资本。 ...

Summary of Key Points from the Conference Call Industry Overview - **Industry**: Oil, Gas, and Chemicals - **Key Trends**: - OPEC+ is expected to fully unwind production cuts, leading to increased oil supply surplus expectations. - Brent crude oil prices fell by 3% month-over-month (MoM) to US$67.3 per barrel in August, indicating weaker prices as peak demand season ends. [2][28] - The International Energy Agency (IEA) projects a surplus of 1.8 million barrels per day (Mb/d) in 2025, increasing to 3.0 Mb/d in 2026. The Energy Information Administration (EIA) forecasts around 1.5 Mb/d for both years. [2][28] Chemical Sector Insights - **Price Movements**: - TDI (Toluene Diisocyanate) average selling price (ASP) increased by 13% MoM, but showed a downward trend due to soft demand and higher supply. [3] - mMDI (Modified MDI) ASP rose by 7% MoM, supported by maintenance periods for some plants. [3] - Refrigerant R32 ASP also increased by 7% MoM, driven by strong producer bargaining power. [3] - **Demand Dynamics**: - Price increases were noted among TiO2 producers and polyester filament businesses, indicating potential for further price hikes in the near term. [4] - Products with tight supply include acetic acid, hydrogen peroxide, refrigerants, and others, suggesting potential price support. [4] Stock Recommendations - **Preferred Sectors**: - Chemical subsectors are favored as beneficiaries of 'anti-involution', particularly: - Fertilizers (Hualu) - Refining/Olefins (Hengli, Baofeng, Satellite) - Products with price hike potential (Wanhua for pMDI, Tongkun for polyester filament, Fufeng/Meihua for MSG, and refrigerants). [5] Risk Factors - **Oil & Gas Sector Risks**: - Fluctuations in crude oil prices and disappointing productivity enhancements could impact the sector. [28] - **Chemical Sector Risks**: - Price volatility due to international oil price changes and macroeconomic uncertainties could affect demand. [29] - **New Materials Sector Risks**: - Technological changes and reliance on policy support pose risks to revenue growth and stability. [30] Price Trends and Spreads - **Chemical Product Prices**: - Significant price changes were observed in various chemical products, with some experiencing declines of over 30% year-over-year (YoY). [27] - For example, butyl acrylate saw a 20.9% decrease MoM, while methanol-coal prices increased by 63.5% YoY. [27] Conclusion - The oil and chemical sectors are facing a complex landscape characterized by supply surpluses, price volatility, and shifting demand dynamics. Investors are advised to monitor these trends closely for potential investment opportunities and risks.

Group 1 - The company Meihua Biological (SH 600873) announced a share buyback of 35.7084 million shares, representing 1.25% of its total share capital of approximately 2.853 billion shares, with a total expenditure of about 352 million RMB [1][1][1] - The share buyback was conducted through centralized bidding, with the lowest purchase price at 9.1 RMB per share and the highest at 10.68 RMB per share, complying with legal regulations and the company's buyback plan [1][1][1] - As of the report date, the market capitalization of Meihua Biological is 31.3 billion RMB [1][1][1] Group 2 - For the fiscal year 2024, the revenue composition of Meihua Biological is as follows: 97.34% from bio-fermentation, 1.9% from pharmaceutical health, and 0.76% from other businesses [1][1][1]

梅花生物科技集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600873 证券简称：梅花生物 公告编号：2025-053 重要内容提示： 回购方案首次披露日 2024/9/24，由公司董事长王爱军提议 回购方案实施期限 2024 年 10 月 11 日~2025 年 10 月 10 日 预计回购金额 30,000万元~50,000万元 √减少注册资本 □用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 3,570.84万股 累计已回购股数占总股本比例 1.25% 累计已回购金额 35,202.44万元 实际回购价格区间 9.10元/股~10.68元/股 一、 回购股份的基本情况 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2024 年 9 月 23 日、2024 年 10 月 11 日召开了公司第十届董事会第十三次会议和 2024 年第二次临 时股东大会，会上审议通过了《关于以集中竞价交易 ...

证券代码：600873 证券简称：梅花生物 公告编号：2025-053 梅花生物科技集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 三、其他事项 重要内容提示： 一、回购股份的基本情况 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2024 年 9 月 23 日、2024 年 10 月 11 日召开了公司第十届董事会第十三次会议和 2024 年第二次临 时股东大会，会上审议通过了《关于以集中竞价交易方式回购公司股份的议案》。 公司于 2024 年 10 月 12 日披露了《梅花生物科技集团股份有限公司关于以集中竞 价交易方式回购股份的回购报告书》，本次回购金额不低于人民币 3 亿元，不超过 人民币 5 亿元，回购股份用于注销，减少注册资本。2024 年 10 月 23 日，公司实 施了首次回购。具体内容详见公司披露在上海证券交易所网站（www.sse.com.cn） 上的相关公告。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市 ...